Vimarsana
Biggest News Aggregation in the World

Cellular Therapeutics News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Cellular Therapeutics. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Cellular Therapeutics Today - Breaking & Trending Today

CSPAN2 Chip Walter Immortality Inc July 13, 2024 - Vimarsana News

CSPAN2 Chip Walter Immortality Inc July 13, 2024

Therapeutics. The biomedical and received his undergraduate degree in Computer Science and a phd in biology from cambridge university. Doctor robert is chairman and ceo of cellularity inc. An accomplished surgeon, biomedical scientists and aviator. Its a graduate of Columbia College in columbia university, engineering and applied science. He also earned his md and phd from cornell university. Doctor Cynthia Kenyon a pioneer in the field of aging. An Vice President of aging research at lifesciences. In Google Alphabet company. She spent many years on the u. S. Avenue at the molecular biologist ...

IN8bio Presents Positive Data Demonstrating Durable 1-year Complete Remission in 100% of Evaluable Patients in Phase 1 Trial of INB-100 - Vimarsana News

IN8bio Presents Positive Data Demonstrating Durable 1-year Complete Remission in 100% of Evaluable Patients in Phase 1 Trial of INB-100

100% of treated leukemia patients achieved durable complete remission at 1-year, including high-risk and relapsed acute myeloid leukemia patients who had previously failed multiple lines of...

OPC Summer 2024: Connecting Oncology Pharmacists With Cutting-Edge Insights and Opportunities to Collaborate - Vimarsana News

OPC Summer 2024: Connecting Oncology Pharmacists With Cutting-Edge Insights and Opportunities to Collaborate

This year’s event from June 20 to 21, 2024, in Austin, Texas, will offer 4.25 BCOP CE hours.

Parsaclisib Added to Ruxolitinib Decreases Spleen Volume and Improves Symptom Scores in Myelofibrosis - Vimarsana News

Parsaclisib Added to Ruxolitinib Decreases Spleen Volume and Improves Symptom Scores in Myelofibrosis

Add-on parsaclisib with ruxolitinib resulted in decreased spleen volume and improved symptom assessment scores in patients with myelofibrosis.

U.S. FDA Approves Bristol Myers Squibb and 2seventy bio's Abecma for Triple-Class Exposed Relapsed or Refractory Multiple Myeloma After Two Prior Lines of Therapy -April 05, 2024 at 09:08 am EDT - Vimarsana News

U.S. FDA Approves Bristol Myers Squibb and 2seventy bio's Abecma for Triple-Class Exposed Relapsed or Refractory Multiple Myeloma After Two Prior Lines of Therapy -April 05, 2024 at 09:08 am EDT

Abecma tripled progression-free survival compared to standard regimens in the Phase 3 KarMMa-3 trial, with a 51% reduction in risk of disease progression or death and a well-established safety...